Plus, President Trump issued an executive order banning TikTok and WeChat, July job gains came in just under 1.8 million, and coronavirus relief bill talks have stalled.
Read MoreTrade Setup Stocks found in this category are low priced stocks priced between .50 and $1, with at least 50k shares of average shares trading per day. The stocks are pausing a trend either up or down, with a new bar over the prior day open or close. These are high reward to risk stocks with the […]
Read MoreBuy Price: $2.00 or better Sell Price: TradersPro Sell Signal CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of diseases associated with aging and metabolic dysfunction. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, type 2 diabetes […]
Read MoreThere is a pretty significant difference in the way different investors perceive a stock in a long-term downward trend. For growth oriented-investors, the longer the downward trend, the less attractive the stock is, simply because the expectation is that the longer, bearish trend will outlast any near-term, bullish sentiment or momentum the stock may see. […]
Read MoreThe market will be ‘fat and flat’ in the near-term according to one Goldman analyst, but this is how investors can play it.
Read MoreThe coronavirus has thrown a wrench in this year’s back-to-school season, but these 2 stocks could still see a boost as students prep for a new school year.
Read More1 stock in the retail sector looks poised to break higher.
Read MoreExperts say these 2 gold stocks may be the best way to take advantage of the metal’s climb higher.
Read MoreBuy Price: $105 or better Sell Price: TradersPro Sell Signal MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to […]
Read MorePlus, weekly jobless claims hit their lowest level in the pandemic era but still came in above 1 million, White House and congressional Democratic negotiators have a self-imposed deadline of Friday to come to agreement on a relief package, and Bausch Health is spinning off is eye care business.
Read More“Coronavirus exhaustion” may not be a real term – but I do believe it’s a real thing. There seems to be a real sense of exhaustion about the pandemic that is contributing to a number of factors in the United States – including, to some degree, the market’s seeming resilience and resistance over the last […]
Read MoreEV stocks are speeding higher this year, but 2 stocks in the group look like buys to these experts.
Read MoreThis ETF may be signaling where the market is headed in the near-term.
Read MoreTrade Setup Buy Target: $9.53 Sell Target: $11.45 Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company’s specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in […]
Read MoreTrade Setup Stocks found in this category are low priced stocks priced between .50 and $1, with at least 50k shares of average shares trading per day. The stocks are pausing a trend either up or down, with a new bar over the prior day open or close. These are high reward to risk stocks with the […]
Read More